Zymeworks Inc.

Approval AI-extracted

zanidatamab

HER2-positive locally advanced or metastatic GEA

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on zanidatamab for HER2-positive locally advanced or metastatic GEA is expected Date TBD.

Primary source · SEC 8-K verified 14h ago

“Pending approval, Jazz expects to commercially launch zanidatamab in the U.S. in this indication”